应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01276 恒瑞医药
交易中 04-01 13:50:46
67.950
+3.450
+5.35%
最高
67.950
最低
63.650
成交量
2,947万
今开
66.650
昨收
64.500
日振幅
6.67%
总市值
4,510亿
流通市值
175.31亿
总股本
66.37亿
成交额
18.06亿
换手率
11.42%
流通股本
2.58亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
恒瑞医药：创新药收入突破163亿，对外许可常态化打开增长新空间
证券市场周刊 · 03-31 16:15
恒瑞医药：创新药收入突破163亿，对外许可常态化打开增长新空间
恒瑞医药披露Myosin抑制剂HRS-1893治疗梗阻性肥厚型心肌病II期研究积极结果
每日经济新闻 · 03-31 10:24
恒瑞医药披露Myosin抑制剂HRS-1893治疗梗阻性肥厚型心肌病II期研究积极结果
恒瑞医药与Braveheart Bio公布HRS/BHB-1893治疗梗阻性肥厚型心肌病二期试验积极结果
美股速递 · 03-30 21:38
恒瑞医药与Braveheart Bio公布HRS/BHB-1893治疗梗阻性肥厚型心肌病二期试验积极结果
营收316亿、净利增超21% 恒瑞医药2025年财报释放强劲动能
中金财经 · 03-30 14:37
营收316亿、净利增超21% 恒瑞医药2025年财报释放强劲动能
【券商聚焦】交银国际维持恒瑞医药(01276)中性评级 指新品放量+国际化共驱高增长
金吾财讯 · 03-30 11:00
【券商聚焦】交银国际维持恒瑞医药(01276)中性评级 指新品放量+国际化共驱高增长
港股异动 | 先声药业(02096)午前涨近8% 恒瑞医药前董事长周云曙正式出任先声药业CEO
智通财经 · 03-27
港股异动 | 先声药业(02096)午前涨近8% 恒瑞医药前董事长周云曙正式出任先声药业CEO
异动解读 | 恒瑞医药盘中大涨5.06%，强劲年报业绩与创新药转型提振市场信心
异动解读 · 03-27
异动解读 | 恒瑞医药盘中大涨5.06%，强劲年报业绩与创新药转型提振市场信心
恒瑞医药创新药收入占比近六成 BD重构国际化价值锚点
21世纪经济报道 · 03-27
恒瑞医药创新药收入占比近六成 BD重构国际化价值锚点
恒瑞医药(600276.SH)：HRS9531注射液获得药物临床试验批准通知书
智通财经 · 03-26
恒瑞医药(600276.SH)：HRS9531注射液获得药物临床试验批准通知书
恒瑞医药将于2026年4月16日后派发末期股息每股0.20元
公告速递 · 03-26
恒瑞医药将于2026年4月16日后派发末期股息每股0.20元
恒瑞医药2025年创新业务发力，营收突破316亿元，利润稳步增长
公告速递 · 03-26
恒瑞医药2025年创新业务发力，营收突破316亿元，利润稳步增长
恒瑞医药(01276)拟向上海瑞宏迪增资2.85亿元
智通财经 · 03-25
恒瑞医药(01276)拟向上海瑞宏迪增资2.85亿元
恒瑞医药2025年年报：营收净利再创新高 创新国际化双轮驱动结硕果
21世纪经济报道 · 03-25
恒瑞医药2025年年报：营收净利再创新高 创新国际化双轮驱动结硕果
恒瑞医药：2025年净利润同比增长21.69%，拟10派2元
老虎资讯综合 · 03-25
恒瑞医药：2025年净利润同比增长21.69%，拟10派2元
恒瑞医药(600276.SH)：SHR-3836注射液获得药物临床试验批
智通财经 · 03-20
恒瑞医药(600276.SH)：SHR-3836注射液获得药物临床试验批
恒瑞医药：1类新药注射用瑞康曲妥珠单抗新增乳腺癌适应症获批
每日经济新闻 · 03-20
恒瑞医药：1类新药注射用瑞康曲妥珠单抗新增乳腺癌适应症获批
财报前瞻 ｜恒瑞医药研发推进与海外商业化成关注点
财报Agent · 03-19
财报前瞻 ｜恒瑞医药研发推进与海外商业化成关注点
港股公告掘金 | 蚂蚁集团收购耀才证券金融的要约已获批准 3月17日复牌
智通财经 · 03-17
港股公告掘金 | 蚂蚁集团收购耀才证券金融的要约已获批准 3月17日复牌
恒瑞医药(600276.SH)：富马酸立康可泮(HRS-5965)胶囊药品上市许可申请获受理
智通财经 · 03-16
恒瑞医药(600276.SH)：富马酸立康可泮(HRS-5965)胶囊药品上市许可申请获受理
恒瑞医药(600276.SH)：SHR-1819注射液联合SHR-1905注射液用于治疗特应性皮炎获批开展临床试验
智通财经 · 03-16
恒瑞医药(600276.SH)：SHR-1819注射液联合SHR-1905注射液用于治疗特应性皮炎获批开展临床试验
加载更多
公司概况
公司名称：
恒瑞医药
所属市场：
SEHK
上市日期：
--
主营业务：
江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。
发行价格：
--
{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":67.95,"timestamp":1775022636886,"preClose":64.5,"halted":0,"volume":29467282,"delay":0,"changeRate":0.0534883720930233,"floatShares":258000000,"shares":6637000000,"eps":1.343234489515971,"marketStatus":"交易中","change":3.45,"latestTime":"04-01 13:50:46","open":66.65,"high":67.95,"low":63.65,"amount":1805936551,"amplitude":0.066667,"askPrice":67.95,"askSize":200,"bidPrice":67.85,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":1.343234489515971,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1775031000000},"marketStatusCode":2,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":64.5,"openAndCloseTimeList":[[1775007000000,1775016000000],[1775019600000,1775030400000]],"volumeRatio":15.229502,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":57.6,"timestamp":1775022644000,"preClose":55.22,"halted":0,"volume":77682700,"delay":0,"premium":"+3.63"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"2623330120","title":"恒瑞医药：创新药收入突破163亿，对外许可常态化打开增长新空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2623330120","media":"证券市场周刊","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623330120?lang=zh_cn&edition=full","pubTime":"2026-03-31 16:15","pubTimestamp":1774944914,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药（600276.SH）发布2025年年度报告。报告显示，公司全年实现营业收入316.29亿元，同比增长13.02%；实现归母净利润77.11亿元，同比增长21.69%；现金流达112.35亿元，同比增长51.36%。报告期间在创新药成果加速转化与对外许可收入常态化入账的双重驱动下，公司业绩实现稳健增长，经营质量持续优化，展现出从研发投入到商业变现的良性循环能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690397891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1580142542.USD","BK0012","BK0060","BK0196","LU1328615791.USD","LU2097828805.USD","LU1023057109.AUD","BK0188","LU1064130708.USD","BK1574","LU1146622755.USD","LU0359201885.HKD","LU2580892789.USD","LU2148510915.USD","BK1161","LU2543165471.USD","LU2328871848.SGD","LU1820825898.SGD","LU2495084118.USD","LU2097828631.EUR","LU1255011170.USD","159992","LU2488822045.USD","LU1655091616.SGD","LU2580892862.HKD","LU0359202008.SGD","BK1191","LU2097828714.EUR","LU2097828474.EUR","LU1997245094.SGD","LU0405327494.USD","LU1997244956.HKD","LU2097828557.USD","LU0359201612.USD","LU1064131003.USD","06978","600276","BK0028","LU1781817850.SGD","LU1969619763.USD","01276","LU0405327148.USD","LU2289578879.USD","BK0239","BK0183","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623637146","title":"恒瑞医药披露Myosin抑制剂HRS-1893治疗梗阻性肥厚型心肌病II期研究积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2623637146","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623637146?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:24","pubTimestamp":1774923855,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月31日，恒瑞医药公众号消息显示，恒瑞医药与BraveheartBio在第75届美国心脏病学会年度科学会议上共同公布了新一代在研心肌肌球蛋白（Myosin）小分子抑制剂HRS-1893（也称BHB-1893）用于梗阻性肥厚型心肌病(oHCM)受试者的II期临床试验数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603313690111336.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690111336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","LU1064131003.USD","LU0359202008.SGD","LU1997245094.SGD","BK0183","LU2328871848.SGD","LU2580892789.USD","LU1023057109.AUD","LU2543165471.USD","LU1820825898.SGD","LU0405327494.USD","LU1146622755.USD","LU2097828474.EUR","LU2097828557.USD","LU0359201612.USD","LU2289578879.USD","BK0012","LU2580892862.HKD","LU1655091616.SGD","BK0028","LU1969619763.USD","LU0359201885.HKD","LU1781817850.SGD","LU1328615791.USD","600276","LU2488822045.USD","LU1997245177.USD","LU1064130708.USD","LU2148510915.USD","BK0060","01276","LU1255011170.USD","BK0188","LU2495084118.USD","BK0239","LU1997244956.HKD","LU1580142542.USD","LU0405327148.USD","LU2097828631.EUR","LU2097828714.EUR","LU2097828805.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110597226","title":"恒瑞医药与Braveheart Bio公布HRS/BHB-1893治疗梗阻性肥厚型心肌病二期试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1110597226","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110597226?lang=zh_cn&edition=full","pubTime":"2026-03-30 21:38","pubTimestamp":1774877897,"startTime":"0","endTime":"0","summary":"恒瑞医药与Braveheart Bio共同宣布，其合作研发的创新药物HRS/BHB-1893在梗阻性肥厚型心肌病的二期临床试验中取得突破性进展。试验数据显示，该药物在主要疗效终点上表现出显著优势，患者的心功能指标与生活质量均获明显改善。此次成果为后续三期临床研究奠定了坚实基础，也为全球梗阻性肥厚型心肌病患者提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0012","BK0196","LU0359202008.SGD","LU1064130708.USD","BK0028","BK0183","600276","LU1997245177.USD","LU1969619763.USD","LU1820825898.SGD","LU1655091616.SGD","BK1191","LU1781817850.SGD","LU2097828714.EUR","LU0359201885.HKD","LU0405327148.USD","LU2488822045.USD","LU1064131003.USD","LU0359201612.USD","LU2289578879.USD","LU1580142542.USD","BK0060","LU1328615791.USD","LU0405327494.USD","LU2097828805.USD","LU2097828631.EUR","LU2097828557.USD","LU2580892789.USD","LU2148510915.USD","LU2495084118.USD","01276","LU1997244956.HKD","LU1146622755.USD","LU1997245094.SGD","LU2097828474.EUR","LU2543165471.USD","LU1023057109.AUD","LU2580892862.HKD","LU1255011170.USD","BK0188","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623701399","title":"营收316亿、净利增超21% 恒瑞医药2025年财报释放强劲动能","url":"https://stock-news.laohu8.com/highlight/detail?id=2623701399","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623701399?lang=zh_cn&edition=full","pubTime":"2026-03-30 14:37","pubTimestamp":1774852622,"startTime":"0","endTime":"0","summary":"3月25日，恒瑞医药发布2025年年度报告。报告期内，公司坚持“科技创新+国际化”双轮驱动战略，实现业绩持续增长，营收和净利均再创新高。全年实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%；归属于上市公司股东的扣除非经常性损益的净利润74.13亿元，同比增长20.00%。创新药销售收入163.42亿元，同比增长26.09%，占药品销售收入比重达58.34%；对外许可收入33.92亿元，同比增长25.62%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260330/32111266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623360351","title":"【券商聚焦】交银国际维持恒瑞医药(01276)中性评级 指新品放量+国际化共驱高增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2623360351","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623360351?lang=zh_cn&edition=full","pubTime":"2026-03-30 11:00","pubTimestamp":1774839632,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，恒瑞医药(01276)2025年收入同比增长13%，符合该机构的预期，毛利率与2024年基本持平，研发/SG&A费用率下降1.5/1.3ppt，反映公司运营效率的持续提升。2025 年公司业绩录得较快增速，主要动力来自创新药销售持续放量及对外授权收入的常态化贡献。2026年重点关注新进医保产品放量节奏、ADC及减重领域重点品种III期数据读出、及丰厚早研管线产生的更多BD机会。基于2025年业绩及未来指引，该机构微调公司2026-27 年盈利预测，维持目标价 69.5 港元/63.18 人民币（01276/600276 CH），当前估值合理，维持中性评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622814803","title":"港股异动 | 先声药业(02096)午前涨近8% 恒瑞医药前董事长周云曙正式出任先声药业CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2622814803","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622814803?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:01","pubTimestamp":1774584119,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，先声药业午前涨近8%，截至发稿，涨7.87%，报12.06港元，成交额4559.2万港元。消息面上，3月25日，先声药业公告披露，恒瑞医药原董事长周云曙正式加盟，获聘首席执行官。先声药业近日发布的年度业绩显示。目前，先声药业已拥有10款上市创新药，还有超5款临近上市创新药，预计于2026-2028年获批，蓄力未来持续增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2495084118.USD","LU1023057109.AUD","LU1146622755.USD","LU1064130708.USD","BK0183","LU0405327494.USD","LU2097828631.EUR","LU0359201612.USD","LU1781817850.SGD","BK0239","BK0012","LU1580142542.USD","BK0188","LU2097828805.USD","BK1191","LU2097828474.EUR","LU1997244956.HKD","BK4588","LU1997245177.USD","LU2580892789.USD","LU2097828714.EUR","LU2580892862.HKD","LU2488822045.USD","LU1255011170.USD","LU2328871848.SGD","LU2543165471.USD","BK0028","LU1655091616.SGD","02096","LU0359201885.HKD","LU1969619763.USD","BK1583","01276","BK0060","LU2148510915.USD","VXUS","LU1997245094.SGD","LU2097828557.USD","BK4585","600276","BK0196","LU1820825898.SGD","LU2289578879.USD","LU0405327148.USD","LU1064131003.USD","LU1328615791.USD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185545662","title":"异动解读 | 恒瑞医药盘中大涨5.06%，强劲年报业绩与创新药转型提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1185545662","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185545662?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:04","pubTimestamp":1774577079,"startTime":"0","endTime":"0","summary":"恒瑞医药今日盘中股价大幅上涨5.06%，引发了市场的广泛关注。消息面上，公司于近日发布了2025年年度报告，业绩表现亮眼。报告显示，公司全年实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%，增速显著超出行业平均水平。这些积极的财务与战略进展，共同构成了推动股价上涨的核心动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622789788","title":"恒瑞医药创新药收入占比近六成 BD重构国际化价值锚点","url":"https://stock-news.laohu8.com/highlight/detail?id=2622789788","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622789788?lang=zh_cn&edition=full","pubTime":"2026-03-27 07:00","pubTimestamp":1774566000,"startTime":"0","endTime":"0","summary":"3月25日，恒瑞医药（600276.SH，01276.HK）发布2025年年度报告。财报显示，全年实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%；归属于上市公司股东的扣除非经常性损益的净利润74.13亿元，同比增长20.00%。这一增速显著超出行业平均水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686095212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686095212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","LU0359201612.USD","BK0028","01276","LU2289578879.USD","LU1064130708.USD","LU2097828474.EUR","LU2097828805.USD","BK0060","BK0196","LU2580892862.HKD","LU1146622755.USD","LU2328871848.SGD","LU0359202008.SGD","LU0405327494.USD","LU2488822045.USD","LU2495084118.USD","BK1574","LU1997245177.USD","LU0405327148.USD","06978","LU1580142542.USD","LU1655091616.SGD","LU2543165471.USD","BK0188","BK1161","LU1064131003.USD","LU1969619763.USD","LU1820825898.SGD","LU1023057109.AUD","LU1781817850.SGD","LU2097828631.EUR","LU1328615791.USD","BK0012","LU1997245094.SGD","BK0239","LU0359201885.HKD","LU1997244956.HKD","159992","LU1255011170.USD","LU2580892789.USD","LU2097828557.USD","BK0183","LU2097828714.EUR","BK1191","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622830485","title":"恒瑞医药(600276.SH)：HRS9531注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622830485","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622830485?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:51","pubTimestamp":1774515073,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS9531注射液的《药物临床试验批准通知书》，将于近期开展临床试验。根据《中华人民共和国药品管理法》及有关规定，经审查，2026年1月7日受理的HRS9531注射液临床试验申请符合药品注册的有关要求，同意本品开展临床试验。申请的适应症：用于降低动脉粥样硬化性心血管疾病患者的主要心血管不良事件风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","LU2580892789.USD","LU0405327494.USD","BK0183","LU1255011170.USD","BK0188","LU1820825898.SGD","BK1191","LU0359202008.SGD","LU1781817850.SGD","LU1580142542.USD","BK0196","LU2097828474.EUR","LU2097828714.EUR","LU0359201885.HKD","LU1997245177.USD","LU1997245094.SGD","LU1997244956.HKD","LU1328615791.USD","LU2289578879.USD","LU2580892862.HKD","BK0012","LU0359201612.USD","LU1064130708.USD","BK0239","LU2543165471.USD","LU2495084118.USD","LU2097828631.EUR","LU1146622755.USD","LU2328871848.SGD","LU2097828805.USD","LU1969619763.USD","LU1023057109.AUD","LU0405327148.USD","LU2488822045.USD","600276","LU2097828557.USD","LU2148510915.USD","01276","BK0028","LU1655091616.SGD","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137906506","title":"恒瑞医药将于2026年4月16日后派发末期股息每股0.20元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137906506","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137906506?lang=zh_cn&edition=full","pubTime":"2026-03-26 06:35","pubTimestamp":1774478157,"startTime":"0","endTime":"0","summary":"恒瑞医药(01276)\n2026年3月25日，恒瑞医药公布，截至2025年12月31日止年度拟派发末期股息，每10股派发2元人民币，即每股0.20元，尚需于2026年4月16日股东大会批准后发放。公司表示，若分红派息记录日公司总股本发生变化，派发方案的每股分配比例将保持不变，并相应调增分配总额。另外，关于港股除净日、股份过户登记的最后时限、记录日期及具体派息日期等事项尚待后续公布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138271280","title":"恒瑞医药2025年创新业务发力，营收突破316亿元，利润稳步增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1138271280","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138271280?lang=zh_cn&edition=full","pubTime":"2026-03-26 06:29","pubTimestamp":1774477778,"startTime":"0","endTime":"0","summary":"恒瑞医药于2025年度实现营业收入316.29亿元，同比增长13.0%；同期录得归属于上市公司股东的利润77.11亿元，同比上升7.7%。报告期内，公司在肿瘤、心血管、免疫和神经系统等多个治疗领域持续深耕，创新药销售收入约163.42亿元，增幅达26.1%，并带动整体业绩稳步提升。公司报告期内在境内外持续推动合作与新药注册申请，提升新产品的临床价值与商业化效率。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622678070","title":"恒瑞医药(01276)拟向上海瑞宏迪增资2.85亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622678070","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622678070?lang=zh_cn&edition=full","pubTime":"2026-03-25 23:20","pubTimestamp":1774452011,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 公布，于2026年3月25日，公司与恒瑞集团、盛迪生物医药基金、深圳迎泰及上海瑞宏迪订立增资协议，以将上海瑞宏迪的注册资本由约人民币1.316亿元增加至约2.303亿元。根据增资协议，公司、恒瑞集团、盛迪生物医药基金及深圳迎泰同意按比例以现金形式出资合共人民币7.5亿元，该公司出资2.85亿元。增资协议完成后，公司、恒瑞集团、盛迪生物医药基金及深圳迎泰将分别继续持有上海瑞宏迪38.0%、28.0%、19.0%及15.0%的股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997245177.USD","BK0183","LU1146622755.USD","LU1023057109.AUD","LU1997244956.HKD","BK0012","LU0359201612.USD","LU2097828557.USD","LU1580142542.USD","LU2097828714.EUR","LU1255011170.USD","LU2580892789.USD","600276","LU1997245094.SGD","LU1820825898.SGD","LU1969619763.USD","LU2289578879.USD","LU0359202008.SGD","BK0060","BK0188","LU0405327148.USD","LU1781817850.SGD","LU2488822045.USD","BK1191","LU2495084118.USD","LU1064131003.USD","LU1064130708.USD","BK0239","LU1655091616.SGD","LU2580892862.HKD","LU0405327494.USD","01276","LU2097828474.EUR","BK0028","BK0196","LU2543165471.USD","LU2328871848.SGD","LU1328615791.USD","LU0359201885.HKD","LU2097828805.USD","LU2148510915.USD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622072044","title":"恒瑞医药2025年年报：营收净利再创新高 创新国际化双轮驱动结硕果","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072044","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622072044?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:22","pubTimestamp":1774448520,"startTime":"0","endTime":"0","summary":"3月25日，恒瑞医药发布2025年年度报告。报告期内，公司坚持“科技创新+国际化”双轮驱动战略，实现业绩持续增长，营收和净利均再创新高。全年实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%；归属于上市公司股东的扣除非经常性损益的净利润74.13亿元，同比增长20.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603253684444032.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253684444032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600276","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167610912","title":"恒瑞医药：2025年净利润同比增长21.69%，拟10派2元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167610912","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167610912?lang=zh_cn&edition=full","pubTime":"2026-03-25 20:47","pubTimestamp":1774442842,"startTime":"0","endTime":"0","summary":"3月25日，$恒瑞医药(01276)$公告称，2025年公司实现营收316.29亿元，同比增长13.02%；净利润77.11亿元，同比增长21.69%。拟向全体股东按每10股派发现金股利2.00元（含税）。小财注：Q3净利润13.01亿，据此计算，Q4净利润19.6亿，环比增长50%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"324431b18d184842b2237adf08e51534","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药：2025年净利润同比增长21.69%，拟10派2元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU2488822045.USD","LU1328615791.USD","LU1997244956.HKD","LU0359201885.HKD","LU1997245094.SGD","01276","LU2328871848.SGD","LU1064131003.USD","BK0012","LU0405327494.USD","BK0196","LU0405327148.USD","LU0359201612.USD","LU1255011170.USD","LU2543165471.USD","LU2097828805.USD","LU2097828474.EUR","BK0239","LU2580892862.HKD","LU1781817850.SGD","LU1580142542.USD","LU1820825898.SGD","LU2097828631.EUR","BK0028","600276","LU1146622755.USD","LU2580892789.USD","BK0183","LU1969619763.USD","LU0359202008.SGD","LU2097828557.USD","LU2148510915.USD","LU1023057109.AUD","LU1997245177.USD","LU1655091616.SGD","LU2097828714.EUR","BK0060","LU2289578879.USD","LU1064130708.USD","BK0188","LU2495084118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620978152","title":"恒瑞医药(600276.SH)：SHR-3836注射液获得药物临床试验批","url":"https://stock-news.laohu8.com/highlight/detail?id=2620978152","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620978152?lang=zh_cn&edition=full","pubTime":"2026-03-20 17:10","pubTimestamp":1773997815,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司上海恒瑞医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-3836注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-3836注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗多发性骨髓瘤。经查询，目前国内外尚无同类药上市。截至目前，SHR-3836注射液相关项目累计研发投入约3,170万元(未经审计)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2580892862.HKD","LU2097828805.USD","LU1064131003.USD","LU1064130708.USD","LU2328871848.SGD","LU1146622755.USD","LU2580892789.USD","LU0359201612.USD","LU1997245177.USD","LU2289578879.USD","BK0060","LU1328615791.USD","LU1969619763.USD","BK0183","LU2097828557.USD","LU0359202008.SGD","LU2543165471.USD","LU2495084118.USD","LU2097828714.EUR","LU1023057109.AUD","BK0239","LU2097828631.EUR","LU1781817850.SGD","LU1997245094.SGD","LU2488822045.USD","600276","LU1580142542.USD","BK0012","LU2097828474.EUR","BK1191","LU1997244956.HKD","BK0188","LU0405327148.USD","LU1820825898.SGD","01276","LU0405327494.USD","LU2148510915.USD","BK0196","BK0028","LU1655091616.SGD","LU0359201885.HKD","LU1255011170.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620378159","title":"恒瑞医药：1类新药注射用瑞康曲妥珠单抗新增乳腺癌适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2620378159","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620378159?lang=zh_cn&edition=full","pubTime":"2026-03-20 17:09","pubTimestamp":1773997757,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月20日，恒瑞医药(600276.SH)公告称，公司子公司苏州盛迪亚生物医药有限公司收到国家药监局通知，批准其自主研发的1类创新药注射用瑞康曲妥珠单抗(SHR-A1811)新增适应症，用于治疗既往接受过一种或以上抗HER2药物治疗的局部晚期或转移性HER2阳性成人乳腺癌患者。该药已于2025年5月首次获批用于HER2突变非小细胞肺癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603203678970213.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603203678970213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1023057109.AUD","LU1255011170.USD","LU2328871848.SGD","LU2097828805.USD","LU0359201885.HKD","BK0183","BK0239","LU1781817850.SGD","LU1820825898.SGD","LU2097828631.EUR","BK0028","LU2097828557.USD","LU2097828714.EUR","LU2495084118.USD","LU2488822045.USD","LU1969619763.USD","LU1997244956.HKD","LU2543165471.USD","LU2580892862.HKD","LU2289578879.USD","LU1328615791.USD","LU1064131003.USD","LU1064130708.USD","LU1146622755.USD","LU2148510915.USD","BK0196","LU1997245094.SGD","01276","LU2097828474.EUR","LU1655091616.SGD","LU2580892789.USD","600276","BK0012","LU0405327148.USD","LU0405327494.USD","BK1191","LU1580142542.USD","BK0060","LU0359201612.USD","LU1997245177.USD","LU0359202008.SGD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118636156","title":"财报前瞻 ｜恒瑞医药研发推进与海外商业化成关注点","url":"https://stock-news.laohu8.com/highlight/detail?id=1118636156","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118636156?lang=zh_cn&edition=full","pubTime":"2026-03-19 10:11","pubTimestamp":1773886299,"startTime":"0","endTime":"0","summary":"恒瑞医药将于2026年03月26日（盘后）发布最新季度业绩，市场关注产品结构升级对毛利率与利润韧性的影响。目前缺乏可核验的一致预测与公司针对本季度的量化指引，暂无法给出本季度营业收入、毛利率、净利润或净利率、调整后每股收益及其同比的预测数据。上季度公司实现营业收入157.61亿、毛利率85.58%、归属于母公司股东的净利润13.01亿、净利率17.52%，调整后每股收益未披露；归母净利润环比变动为-49.49%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 ｜恒瑞医药研发推进与海外商业化成关注点","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620241656","title":"港股公告掘金 | 蚂蚁集团收购耀才证券金融的要约已获批准 3月17日复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2620241656","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620241656?lang=zh_cn&edition=full","pubTime":"2026-03-17 09:04","pubTimestamp":1773709477,"startTime":"0","endTime":"0","summary":"重大事项：恒瑞医药(01276)：SHR-1819注射液、SHR-1905注射液获得药物临床试验批准通知书复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药监局批准白云山(00874)：虚汗停颗粒用于儿童反复呼吸道感染的临床试验申请获批派格生物医药-B(02565)与腾瑞制药达成派达康中国大陆独家商业化合作 商业化目标累计销售规","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"808c1f0b8ebd0042a82fe4057566a434","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","VXUS","BK4585","01276","BK1515","LU0359201612.USD","BK1147","LU0359202008.SGD","01428","HK0000320223.HKD","HK0000306685.HKD","BK1606","BK4588","00874","BK1161","BK1191","HK0000165453.HKD","LU0359201885.HKD","06688","BK1521","LU1023057109.AUD","LU2543165471.USD","02565","BK1197","HK0000320264.USD","02696"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619645660","title":"恒瑞医药(600276.SH)：富马酸立康可泮(HRS-5965)胶囊药品上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2619645660","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619645660?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:22","pubTimestamp":1773652966,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司子公司成都盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司富马酸立康可泮胶囊的药品上市许可申请获国家药监局受理。富马酸立康可泮胶囊是一种补体因子B抑制剂，可抑制补体介导的血管内外溶血反应，提升血红蛋白水平。截至目前，HRS-5965胶囊相关项目累计研发投入约25,150万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","LU0405327148.USD","LU1255011170.USD","LU0405327494.USD","LU0359201885.HKD","LU2097828714.EUR","BK0028","600276","LU0359202008.SGD","LU1064131003.USD","LU1146622755.USD","LU1997245094.SGD","LU2097828557.USD","LU2097828631.EUR","BK1191","LU2328871848.SGD","LU1580142542.USD","LU2488822045.USD","LU2580892862.HKD","LU1655091616.SGD","LU1820825898.SGD","LU2148510915.USD","LU1997244956.HKD","BK0196","LU2097828474.EUR","LU2097828805.USD","LU2289578879.USD","LU1997245177.USD","LU2495084118.USD","LU2580892789.USD","LU1969619763.USD","BK0239","LU1023057109.AUD","LU1328615791.USD","BK0060","LU1064130708.USD","LU1781817850.SGD","LU2543165471.USD","LU0359201612.USD","01276","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619565624","title":"恒瑞医药(600276.SH)：SHR-1819注射液联合SHR-1905注射液用于治疗特应性皮炎获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2619565624","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619565624?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:17","pubTimestamp":1773652643,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司广东恒瑞医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-1819注射液、SHR-1905注射液的《药物临床试验批准通知书》。经审查，2025年12月18日受理的SHR-1819注射液、SHR-1905注射液符审批结论合药品注册的有关要求，同意开展临床试验。申请的适应症：SHR-1819注射液联合SHR-1905注射液用于治疗特应性皮炎。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","LU0359201885.HKD","LU2488822045.USD","BK0012","LU2148510915.USD","LU0359202008.SGD","LU1146622755.USD","BK0060","01276","LU1255011170.USD","LU2097828557.USD","LU2543165471.USD","LU2495084118.USD","LU2580892862.HKD","LU1023057109.AUD","LU2328871848.SGD","LU1820825898.SGD","LU1064131003.USD","BK0239","LU2097828631.EUR","600276","LU2097828805.USD","LU2580892789.USD","BK0183","LU0405327494.USD","BK0188","LU1655091616.SGD","LU1064130708.USD","LU0359201612.USD","LU2097828474.EUR","LU2097828714.EUR","LU1328615791.USD","BK1191","BK0028","LU1969619763.USD","LU1997245094.SGD","LU1997245177.USD","LU2289578879.USD","LU1997244956.HKD","LU0405327148.USD","LU1580142542.USD","LU1781817850.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":-0.0301},{"period":"3month","weight":-0.0947},{"period":"6month","weight":-0.3146},{"period":"1year","weight":0.4642},{"period":"ytd","weight":-0.0947}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0692},{"period":"3month","weight":-0.0329},{"period":"6month","weight":-0.0916},{"period":"1year","weight":0.0722},{"period":"ytd","weight":-0.0329}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}